The global radiopharmaceuticals market size was USD 5.97 billion in 2023, calculated at USD 6.74 billion in 2024 and is projected to surpass around USD 13.67 billion by 2033, expanding at a CAGR of 8.2% from 2024 to 2033.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Radiopharmaceuticals Market
5.1. COVID-19 Landscape: Radiopharmaceuticals Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Radiopharmaceuticals Market, By Radioisotope
8.1. Radiopharmaceuticals Market, by Radioisotope, 2024-2033
8.1.1. Iodine I
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Gallium 68
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Technetium 99m
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Fluorine 18
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Radiopharmaceuticals Market, By Application
9.1. Radiopharmaceuticals Market, by Application, 2024-2033
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Radiopharmaceuticals Market, By Type
10.1. Radiopharmaceuticals Market, by Type, 2024-2033
10.1.1. Diagnostic
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Therapeutic
10.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Radiopharmaceuticals Market, By End User
11.1. Radiopharmaceuticals Market, by End User, 2024-2033
11.1.1. Hospitals and clinics
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Medical Imaging centers
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Radiopharmaceuticals Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.1.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.3. Market Revenue and Forecast, by Type (2021-2033)
12.1.4. Market Revenue and Forecast, by End User (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Type (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Type (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Type (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Type (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Radioisotope (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Type (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End User (2021-2033)
Chapter 13. Company Profiles
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Iso-Tex Diagnostics, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Jubilant Pharmova Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. General Electric Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lantheus Holdings, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Eli Lilly and Company
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Siemens AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Curium Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cardinal Health Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample